FR3081870B1 - Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie - Google Patents

Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie Download PDF

Info

Publication number
FR3081870B1
FR3081870B1 FR1800533A FR1800533A FR3081870B1 FR 3081870 B1 FR3081870 B1 FR 3081870B1 FR 1800533 A FR1800533 A FR 1800533A FR 1800533 A FR1800533 A FR 1800533A FR 3081870 B1 FR3081870 B1 FR 3081870B1
Authority
FR
France
Prior art keywords
epitopes
mono
peptide compounds
vaccines against
against leishmania
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1800533A
Other languages
English (en)
Other versions
FR3081870A1 (fr
Inventor
Goncalves Rachel Bras
Jean Loup Lemesre
Amel Garnaoui
Elodie Petitdidier-Lesin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherche pour le Developpement IRD
Institut Pasteur de Tunis
Original Assignee
Institut de Recherche pour le Developpement IRD
Institut Pasteur de Tunis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherche pour le Developpement IRD, Institut Pasteur de Tunis filed Critical Institut de Recherche pour le Developpement IRD
Priority to FR1800533A priority Critical patent/FR3081870B1/fr
Priority to EP19730700.2A priority patent/EP3801608A1/fr
Priority to US17/059,399 priority patent/US11559575B2/en
Priority to PCT/EP2019/064088 priority patent/WO2019243018A1/fr
Priority to TNP/2020/000219A priority patent/TN2020000219A1/fr
Priority to BR112020024211-0A priority patent/BR112020024211A2/pt
Publication of FR3081870A1 publication Critical patent/FR3081870A1/fr
Application granted granted Critical
Publication of FR3081870B1 publication Critical patent/FR3081870B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des épitopes ainsi que des composés peptidiques mono- ou multi-épitopiques, issus des protéines PSA, H2B et LmRAB de Leishmania, ainsi que des compositions pharmaceutiques et des vaccins destinés à être utilisés contre une ou plusieurs Leishmanies.
FR1800533A 2018-05-30 2018-05-30 Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie Active FR3081870B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1800533A FR3081870B1 (fr) 2018-05-30 2018-05-30 Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie
EP19730700.2A EP3801608A1 (fr) 2018-05-30 2019-05-29 Composes peptidiques multiepitopiques et vaccins contre la leishmaniose
US17/059,399 US11559575B2 (en) 2018-05-30 2019-05-29 Multi-epitopic peptide compounds and vaccines against leishmaniasis
PCT/EP2019/064088 WO2019243018A1 (fr) 2018-05-30 2019-05-29 Composes peptidiques multiepitopiques et vaccins contre la leishmaniose
TNP/2020/000219A TN2020000219A1 (fr) 2018-05-30 2019-05-29 Composes peptidiques multiepitopiques et vaccins contre la leishmaniose
BR112020024211-0A BR112020024211A2 (pt) 2018-05-30 2019-05-29 compostos de peptídeo multiepitópico e vacinas contra leishmaniose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1800533 2018-05-30
FR1800533A FR3081870B1 (fr) 2018-05-30 2018-05-30 Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie

Publications (2)

Publication Number Publication Date
FR3081870A1 FR3081870A1 (fr) 2019-12-06
FR3081870B1 true FR3081870B1 (fr) 2024-04-19

Family

ID=65494127

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1800533A Active FR3081870B1 (fr) 2018-05-30 2018-05-30 Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie

Country Status (6)

Country Link
US (1) US11559575B2 (fr)
EP (1) EP3801608A1 (fr)
BR (1) BR112020024211A2 (fr)
FR (1) FR3081870B1 (fr)
TN (1) TN2020000219A1 (fr)
WO (1) WO2019243018A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705358B1 (fr) 1993-05-13 1995-08-04 Orstom Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques.
FR3000402A1 (fr) 2012-12-28 2014-07-04 Vibrac Composes peptidiques mono-ou multi-epitopiques destines a la prevention et au traitement des leishmanioses
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
BR112015032978B1 (pt) 2013-07-02 2022-08-16 Institut De Recherche Pour Le Développement Método de diagnóstico para a detecção de anticorpos indicativos de leishmania sul americana e kit de diagnóstico para detecção de anticorpos antileishmaniose
FR3014103B1 (fr) 2013-11-29 2019-08-16 Institut De Recherche Pour Le Developpement (Ird) Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention

Also Published As

Publication number Publication date
US11559575B2 (en) 2023-01-24
TN2020000219A1 (fr) 2022-07-01
FR3081870A1 (fr) 2019-12-06
BR112020024211A2 (pt) 2021-02-17
WO2019243018A1 (fr) 2019-12-26
EP3801608A1 (fr) 2021-04-14
US20210213114A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
CY1119436T1 (el) Σκευασμα για αντισωμα εναντι- 4 7
BR112018071612A2 (pt) polipeptídeos biespecíficos inovadores contra cd137
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA40151A1 (fr) Vaccins de recombinaison fmdv et leurs utilisations
MA40902B1 (fr) Vaccins hpv16 thérapeutiques
MY166045A (en) Abeta antibody formulation
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
EA202091012A1 (ru) Композиции фосфорилированных тау-пептидов и их применения
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EA202192405A1 (ru) Составы антител против il-36r
MX2020001885A (es) Formulaciones de daptomicina.
MY190102A (en) Tolerogenic dna vaccine
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20191206

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7